Bright Minds Biosciences Inc. - common stock — Rendiconto Finanziario (NASDAQ:DRUG)

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York.

DRUG

Financials

Bright Minds Biosciences Inc. - common stock

Notizie

Piper Sandler alza il target su Bright Minds grazie ai progressi dei programmi

Jefferies avvia la copertura su Bright Minds con rating buy sul farmaco per l’epilessia

BTIG conferma il rating su Bright Minds Biosciences per il potenziale nel trattamento delle crisi epilettiche

H.C. Wainwright alza il target su Bright Minds a 145$ sui dati trial

Bright Minds stock price target raised to $145 by H.C. Wainwright on trial data

Bright Minds Biosciences chiude un’offerta pubblica da 175 milioni di dollari

Bright Minds Biosciences closes $175 million public offering

Bright Minds Biosciences fissa il prezzo dell’offerta pubblica a 90 dollari per azione

Bright Minds Biosciences prices public offering at $90 per share

Bright Minds Biosciences fissa il prezzo dell’offerta pubblica a 175 milioni di dollari

Bright Minds Biosciences prices $175 million public offering

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating